Caravan Health Extends Deadline for 2018 ACO Participation to April 30, 2017

Published on:

April 20, 2017 – Kansas City, MO – Providers who want to take advantage of value-based reimbursements and avoid MACRA penalties in 2018 must act fast – Caravan Health, the market leader in Accountable Care Organizations (ACOs), has extended its deadline for consideration in a 2018 ACO to April 30, 2017.

Caravan Health urges providers to visit their website – caravanhealth.com/apply/ – and fill out a non-binding letter of interest (LOI) to begin the ACO process. Once providers submit an LOI, they will have until June 30 to complete the application process.

“Filling out the non-binding LOI is the first step in transitioning away from volume to value-based care,” says Lynn Barr, MPH, CEO of Caravan Health. “Caravan Health has a 100% application success rate and our expert team will provide guidance every step of the way.”

Ms. Barr states that 124 providers have submitted LOIs to Caravan Health this year and expects up to 200 by the April deadline.

“Our data shows ACO participation is the best option for transforming primary care, increasing revenue and earning MACRA bonuses,” says Barr. “Providers are realizing that they can’t risk waiting another year – the time to join an ACO is now.”

Caravan Health is holding an informational webinar the next two weeks to provide an easy to follow roadmap and address pressing questions. The webinar will take place Friday, April 21 and Friday, April 28 at 8:30 a.m. PT/10:30 a.m. CT/11:30 a.m. ET.  Participants may register at caravanhealth.com/upcoming-events/.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.